Tanvex BioPharma Inc (6541) — Cash Flow-to-Debt Ratio
Tanvex BioPharma Inc (6541) has a Cash Flow-to-Debt Ratio of -0.07x as of December 2025, meaning its operating cash flow of NT$-166.26 Million could theoretically repay 0% of its total liabilities (NT$2.27 Billion) in one year. See 6541 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tanvex BioPharma Inc Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Tanvex BioPharma Inc across 13 annual periods. Also explore how fast is Tanvex BioPharma Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Tanvex BioPharma Inc (2013–2025)
Year-by-year debt coverage analysis for Tanvex BioPharma Inc. For market capitalisation and broader financial context, see market cap of Tanvex BioPharma Inc.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.44x | NT$-1.01 Billion | NT$2.27 Billion | ▲ +29.0% |
| 2024 | -0.62x | NT$-1.15 Billion | NT$1.84 Billion | ▲ +15.4% |
| 2023 | -0.74x | NT$-1.43 Billion | NT$1.94 Billion | ▼ -12.3% |
| 2022 | -0.66x | NT$-1.33 Billion | NT$2.03 Billion | ▲ +9.0% |
| 2021 | -0.72x | NT$-1.39 Billion | NT$1.92 Billion | ▲ +29.2% |
| 2020 | -1.02x | NT$-1.79 Billion | NT$1.75 Billion | ▲ +70.9% |
| 2019 | -3.50x | NT$-1.90 Billion | NT$542.12 Million | ▲ +42.4% |
| 2018 | -6.08x | NT$-1.61 Billion | NT$263.92 Million | ▼ -12.3% |
| 2017 | -5.42x | NT$-1.21 Billion | NT$223.78 Million | ▼ -94.5% |
| 2016 | -2.79x | NT$-833.43 Million | NT$299.25 Million | ▲ +50.6% |
| 2015 | -5.64x | NT$-684.20 Million | NT$121.41 Million | ▲ +15.5% |
| 2014 | -6.67x | NT$-434.17 Million | NT$65.09 Million | ▼ -132.5% |
| 2013 | -2.87x | NT$-239.86 Million | NT$83.63 Million | — |